Viralytics - Termination of coverage
Edison Investment Research is terminating coverage on Viralytics (VLA). Please note you should no longer rely on any previous research or estimates...
37 Views
Is Merck Paying Peanuts to Viralytics for Full Access to Its Oncolytic Immunotherapy Drug Candidate?
The Merck DealThe competition between the leading checkpoint inhibitor cancer drugs Opdivo/Yervoy (Bristol Myers Squibb Co (BMY US) ) and Keytruda...
270 Views
Aussie Healthcare Daily: 7 Dec 2017
The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare companies as well as developments and trends in...
312 Views
Viralytics - Looking towards pivotal Cavatak combo studies
Viralytics continues to report impressive preliminary data for Cavatak in combination with immune checkpoint inhibitors (ICIs), whether...
112 Views
Aussie Healthcare Daily: 4 Dec 2017
The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare companies as well as developments and trends in...
306 Views
No more insights